ロード中...
Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
BACKGROUND: The hypoxia-activated prodrug TH-302 is reduced at its nitroimidazole group and selectively under hypoxic conditions releases the DNA cross-linker bromo-isophosphoramide mustard (Br-IPM). Here, we have explored the effect of Chk1 inhibition on TH-302-mediated pharmacological activities....
保存先:
| 出版年: | BMC Cancer |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2015
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4453293/ https://ncbi.nlm.nih.gov/pubmed/25994202 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1387-6 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|